Rin Institute Inc.

National Cancer Center

National Cancer Center Japan

The University of Tokyo

Riken Corporation

Nanocarrier Co., Ltd.

Yasuhiro Matsumura

Masahiro Yasunaga

Shingo Hanaoka

Shino Manabe

Shinji Saijou

Shinji Saijo

Ryo Tsumura

Kazunori Kataoka

Nobuhiro Nishiyama

Yasuki Kato

Yutaka Miura

Hirobumi Fuchigami

Yoshikatsu Koga

Yoshiyuki Yamamoto

Ryuta Sato

Yohei Hisata

Takahiro Anzai

An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.

Anti-TMEM-180 antibody, anticancer drug and cancer testing method

Cancer-cell-specific anti-TMEM-180 monoclonal antibody, anticancer drug, and cancer testing method

The present invention provides an antibody beneficial for treatment of a solid tumor, an antibody-drug conjugate thereof, and an anticancer agent comprising these. The present invention provides, for example, an antibody that binds to tissue factor or an antigen-binding fragment thereof, wherein the antibody has a dissociation rate constant kd of 5&#xd7;10sor more and an association rate constant Ka of 1&#xd7;10Msor more.

Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same

The present invention relates to an antibody-drug conjugate (ADC) and a composition containing the conjugate for use in treating cancer. According to the present invention, provided are an ADC of an antibody specific to insoluble fibrin and a drug in which a linker linking the antibody and the drug has a plasmin cleavage sequence, and a pharmaceutical composition containing the ADC for use in treating cancer.

Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate

[Problem] The present invention provides an antibody that binds to TMEM132A, an anticancer agent and a cancer test method. [Solution] An antibody that binds to TMEM132A.

Antibody binding to TMEM132A, anticancer agent, and cancer test method

Cancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method

Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.

Anti-tissue factor monoclonal antibody

With the intention of providing an antibody which does not bind to fibrinogen and which has a high affinity for and a high specificity to insoluble fibrin, it is found that a site comprising the amino acids at positions 231 to 246 of the fibrinogen B&#x3b2; chain and a site comprising the amino acids at positions 232 to 246 of the fibrinogen &#x3b3; chain are bound to each other in a fibrinogen molecule. Further, it is shown that when fibrinogen is converted to insoluble fibrin, the binding is released, and these sites are exposed. It is also found that antibodies obtained by immunization with these sites do not bind to fibrinogen and have high affinity for and high specificity to insoluble fibrin.

Antibody against insoluble fibrin

Growing community of inventors

Chiba, Japan

Yasuhiro Matsumura